Reducing renal uptake of111In-DOTATOC: A comparison among various basic amino acids
Purpose: Several studies have reported significant renal toxicity after the use of a high dose of90Y-DOTATOC. Thus, renal protection is necessary in treatments with90Y-DOTA Tyr3-octroetide (DOTATOC). The infusion of certain positively charged amino acids has been shown to effectively reduce renal uptake of DOTATOC. In this study, we compared the effectiveness of three kinds of amino acids, D-lysine (lysine),L-arginine (arginine) and histidine, on renal protection in healthy rats and tried to determine which one was the most effective.Methods: Twenty SD healthy male rats were divided into 4 groups: lysine, histidine, arginine, and control. The rats were injected with a dose of 400 mg/kg of amono acid or 2 ml of phosphate-buffered saline (PBS) (as control) intraperitoneally. All rats were sacrificed at 4 hrs after the injection of 1 MBq111In-DOTATOC. Samples of the kidney were taken and weighed carefully. The counts of radioactivity were measured by a gamma counter and renal concentrations were calculated and expressed as percent injected dose per gram (% ID/g).Results: The renal uptake of111In-DOTATOC was significantly lower for all three kinds of amino acids when compared to the control group. The renal uptake of111In-DOTATOC in the lysine group was significantly lower than those in the histidine and arginine groups. The renal uptake of111In-DOTATOC in the histidine group was lower than that in the arginine group, but no statistical difference was noted.Conclusion: Among these three amino acids, lysine had the best reduction rate of renal uptake of DOTATOC. Histidine was more effective than arginine but no statistical difference was noted.
Key wordsDOTATOC indium-111 lysine histidine arginine
- 12.Bodei P, Cremonesi M, Soboli S, Grana C, Bartolomei M, Rocca P, et al. Receptor-mediated radionuclide therapy with90Y-DOTATOC in association with amino acid infusion: a phase 1 study.Eur J Nucl Med 2003; 30: 207–216.Google Scholar
- 13.Waldherr C, Pless M, Maecke HR, Schumacher T, Crazzolara A, Nitzsche EU, et al. Tumor response and clinical benefit in neuroendocrine tumors after 74. GBq (90)Y-DOTATOC.J Nuch Med 2002; 43: 610–616.Google Scholar
- 18.Macke HR, Béhé M, Froidevaux S, Heppler A, Jermann E. DOTA-d-Phe(1)-Tyr(3)-octreotide (DOTATOC): a unique metallic radionuclides.J Nucl Med 1997; 38: 18P.Google Scholar
- 24.de-Jong M, Bakker WH, Breeman WAP, Bernard BF, Hofland LJ, Visser TJ, et al. Pre-clinical comparison of [DTPA0] octreotide, [DTPA0, Tyr3] octreotide and [DOTA0, Tyr3] octreotide as carriers for somatostain receptor-targeted scintigraphy and radionuclide therapy.Int J Cancer 1998; 75: 406–411.PubMedCrossRefGoogle Scholar
- 30.Rabbani GH, Sack DA, Ahmed S, Peterson JW, Saha SK, Marni F, et al. Antidiarrheal effects ofl-histidine supplemented rice-based oral rehydration solution in the treatment of male adults with severe cholera in Bangladesh: a doubleblind, randomized trial.J Infect Dis 2005; 191: 1507–1514.PubMedCrossRefGoogle Scholar